Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725916 | 0.91 | CYP2C9 (0.43) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL1178368 | 0.87 | CYP2C9 (0.48) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL3737295 | 0.84 | ALDH1A1 (0.48) | CYP2C9CYP2C19ALDH1A1HPGDMAPK1 | |
| SCHEMBL23501601 | 0.75 | CYP2C9 (0.50) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL23501603 | 0.74 | CYP2C9 (0.47) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL23501684 | 0.74 | CYP2C9 (0.49) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL25188374 | 0.73 | CYP2C9 (0.43) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL30542910 | 0.73 | CYP2C9 (0.43) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL1092469 | 0.72 | CYP2C9 (0.51) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL31405429 | 0.72 | CYP2C9 (0.48) | CYP2C9CYP2C19CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598208-B2 | Pyridine derivatives as S1P1/EDG1 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-03 | — | — | US | disclosed |
| EP-2069335-B1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-8288554-B2 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2195311-B1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-01 | — | — | US | disclosed |
| EP-2195311-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2010-06-16 | — | — | EP | disclosed |
| EP-2069335-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
| WO-2008029370-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | CD4, FCGRT, CD47 | CYP2C9 1431/4885CYP2C19 891/4885CA12 4868/4885 |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | CYP2C9 4105/4885CYP2C19 3103/4885CA12 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.